
ACOG Stock Forecast & Price Target
ACOG Analyst Ratings
Bulls say
Alpha Cognition is a biopharmaceutical company with a strong focus on the commercial manufacturing and sales of its lead drug, ZUNVEYL. Their current financial results and forecasts show strong potential for revenue growth and net profitability, with a 12-month price objective of $18 per share. However, potential risks include challenges in achieving sales traction and market uptake for ZUNVEYL, as well as setbacks in clinical testing and potential dilution risk in the medium to long-term.
Bears say
Alpha Cognition is a biopharmaceutical company currently conducting or planning to initiate multiple clinical trials for its lead product, ZUNVEYL, which is expected to provide important real-world evidence and drive future commercial opportunities. Additionally, the company recently settled a payment agreement with Galantos Pharma, adding to its stable financial position, and appointed a new director with significant experience in the biopharmaceutical industry and a history of successful financial and operational leadership. These positive developments support the company's potential for long-term growth, making Alpha Cognition a promising investment opportunity.
This aggregate rating is based on analysts' research of Alpha Cognition Inc and is not a guaranteed prediction by Public.com or investment advice.
ACOG Analyst Forecast & Price Prediction
Start investing in ACOG
Order type
Buy in
Order amount
Est. shares
0 shares